Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ROBERT A WOLFF and GAURI R VARADHACHARY.
ROBERT A WOLFF
Connection Strength
6.545
GAURI R VARADHACHARY
  1. Current and Evolving Therapies for Metastatic Pancreatic Cancer: Are We Stuck With Cytotoxic Chemotherapy? J Oncol Pract. 2016 09; 12(9):797-805.
    View in: PubMed
    Score: 0.589
  2. The war on pancreatic cancer: we are not there yet. Oncology (Williston Park). 2014 Jan; 28(1):80-1.
    View in: PubMed
    Score: 0.490
  3. The war on pancreatic cancer: are we gaining ground? Oncology (Williston Park). 2010 Dec; 24(14):1335-6.
    View in: PubMed
    Score: 0.395
  4. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006 Aug; 13(8):1035-46.
    View in: PubMed
    Score: 0.292
  5. Borderline resectable pancreatic cancer. Curr Treat Options Gastroenterol. 2005 Oct; 8(5):377-84.
    View in: PubMed
    Score: 0.276
  6. Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer. JCO Precis Oncol. 2019; 3.
    View in: PubMed
    Score: 0.181
  7. First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2019 Feb; 26(2):619-627.
    View in: PubMed
    Score: 0.171
  8. Dynamic changes during the treatment of pancreatic cancer. Oncotarget. 2018 Mar 13; 9(19):14764-14790.
    View in: PubMed
    Score: 0.163
  9. Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma. BMC Cancer. 2016 08 22; 16:668.
    View in: PubMed
    Score: 0.147
  10. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol. 2011 Aug 01; 29(22):3037-43.
    View in: PubMed
    Score: 0.103
  11. Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial. Cancer Chemother Pharmacol. 2011 Dec; 68(6):1431-8.
    View in: PubMed
    Score: 0.101
  12. The integration of chemoradiation in the care of patient with localized pancreatic cancer. Cancer Radiother. 2009 Apr; 13(2):123-43.
    View in: PubMed
    Score: 0.087
  13. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol. 2009 Jun 01; 27(16):2598-603.
    View in: PubMed
    Score: 0.087
  14. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer. 2008 Oct 15; 113(8):2046-52.
    View in: PubMed
    Score: 0.085
  15. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008 Jul 20; 26(21):3487-95.
    View in: PubMed
    Score: 0.084
  16. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008 Jul 20; 26(21):3496-502.
    View in: PubMed
    Score: 0.084
  17. Adjuvant therapy for adenocarcinoma of the pancreas: analysis of reported trials and recommendations for future progress. Ann Surg Oncol. 2008 Oct; 15(10):2773-86.
    View in: PubMed
    Score: 0.084
  18. Clinicopathologic features and treatment strategies for patients with pancreatic adenocarcinoma and ovarian metastases. Gynecol Oncol. 2008 Mar; 108(3):515-9.
    View in: PubMed
    Score: 0.082
  19. Future chemoradiation strategies in pancreatic cancer. Semin Oncol. 2007 Aug; 34(4):335-46.
    View in: PubMed
    Score: 0.078
  20. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation. Int J Radiat Oncol Biol Phys. 2022 11 01; 114(3):444-453.
    View in: PubMed
    Score: 0.055
  21. PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer. BMC Cancer. 2022 Jan 03; 22(1):14.
    View in: PubMed
    Score: 0.053
  22. Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. J Gastrointest Oncol. 2021 Oct; 12(5):2268-2274.
    View in: PubMed
    Score: 0.052
  23. Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Cancer Med. 2021 08; 10(15):5041-5050.
    View in: PubMed
    Score: 0.052
  24. Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials. JAMA Oncol. 2021 May 01; 7(5):693-699.
    View in: PubMed
    Score: 0.051
  25. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Ann Surg. 2021 04 01; 273(4):806-813.
    View in: PubMed
    Score: 0.051
  26. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol. 2021 01; 22(1):118-131.
    View in: PubMed
    Score: 0.050
  27. Predictive Modeling for Voxel-Based Quantification of Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma (PDAC): A Multi-Institutional Study. Cancers (Basel). 2020 Dec 05; 12(12).
    View in: PubMed
    Score: 0.049
  28. Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma. Pancreatology. 2021 Jan; 21(1):200-207.
    View in: PubMed
    Score: 0.049
  29. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2020 09 01; 155(9):832-839.
    View in: PubMed
    Score: 0.049
  30. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Cancer Med. 2020 08; 9(15):5406-5415.
    View in: PubMed
    Score: 0.048
  31. Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. Ann Surg. 2020 06; 271(6):996-1002.
    View in: PubMed
    Score: 0.048
  32. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Pancreatology. 2020 Apr; 20(3):501-504.
    View in: PubMed
    Score: 0.046
  33. An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unresectable locally advanced pancreatic cancer (OncoPaC-1): Technical details and study protocol. Endosc Ultrasound. 2020 Jan-Feb; 9(1):24-30.
    View in: PubMed
    Score: 0.046
  34. Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer. Clin Cancer Res. 2020 03 15; 26(6):1385-1394.
    View in: PubMed
    Score: 0.046
  35. Expression of Epithelial-Mesenchymal Transition Markers in Treated Pancreatic Ductal Adenocarcinoma. Pancreas. 2019 Nov/Dec; 48(10):1367-1372.
    View in: PubMed
    Score: 0.046
  36. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA Oncol. 2019 Jun 01; 5(6):824-830.
    View in: PubMed
    Score: 0.045
  37. Novel EUS-guided brachytherapy treatment of pancreatic cancer with phosphorus-32 microparticles: first United States experience. VideoGIE. 2019 May; 4(5):223-225.
    View in: PubMed
    Score: 0.044
  38. Retrospective Analysis of Taxane-Based Therapy in Small Bowel Adenocarcinoma. Oncologist. 2019 06; 24(6):e384-e386.
    View in: PubMed
    Score: 0.043
  39. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. Gastroenterology. 2019 01; 156(1):108-118.e4.
    View in: PubMed
    Score: 0.042
  40. A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2018 12 01; 24(23):5883-5894.
    View in: PubMed
    Score: 0.042
  41. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. J Hematol Oncol. 2018 05 30; 11(1):71.
    View in: PubMed
    Score: 0.042
  42. Open Pancreaticoduodenectomy Case Volume Predicts Outcome of Laparoscopic Approach: A Population-based Analysis. Ann Surg. 2018 03; 267(3):552-560.
    View in: PubMed
    Score: 0.041
  43. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. Cancer. 2018 04 15; 124(8):1701-1709.
    View in: PubMed
    Score: 0.041
  44. Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients. Ann Oncol. 2018 01 01; 29(1):223-229.
    View in: PubMed
    Score: 0.040
  45. Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater. Oncologist. 2018 03; 23(3):277-e26.
    View in: PubMed
    Score: 0.040
  46. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2017 Nov 01; 152(11):1048-1056.
    View in: PubMed
    Score: 0.040
  47. Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy. Pancreas. 2017 10; 46(9):1180-1187.
    View in: PubMed
    Score: 0.040
  48. Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Oncotarget. 2017 Oct 20; 8(50):87163-87173.
    View in: PubMed
    Score: 0.039
  49. Prognostic Significance of New AJCC Tumor Stage in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Therapy. Am J Surg Pathol. 2017 Aug; 41(8):1097-1104.
    View in: PubMed
    Score: 0.039
  50. Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC. Adv Radiat Oncol. 2017 Jul-Sep; 2(3):403-415.
    View in: PubMed
    Score: 0.038
  51. Reduced expression of argininosuccinate synthetase 1 has a negative prognostic impact in patients with pancreatic ductal adenocarcinoma. PLoS One. 2017; 12(2):e0171985.
    View in: PubMed
    Score: 0.038
  52. Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. Ann Surg Oncol. 2017 Jul; 24(7):2031-2039.
    View in: PubMed
    Score: 0.038
  53. A predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patients. Support Care Cancer. 2017 06; 25(6):1809-1817.
    View in: PubMed
    Score: 0.038
  54. Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival. Am J Surg Pathol. 2016 12; 40(12):1653-1660.
    View in: PubMed
    Score: 0.037
  55. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study. Cancer. 2017 May 15; 123(6):1011-1017.
    View in: PubMed
    Score: 0.037
  56. Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy? Int J Radiat Oncol Biol Phys. 2017 02 01; 97(2):323-332.
    View in: PubMed
    Score: 0.037
  57. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. J Gastrointest Surg. 2017 01; 21(1):164-174.
    View in: PubMed
    Score: 0.037
  58. Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. J Gastrointest Surg. 2016 12; 20(12):1975-1985.
    View in: PubMed
    Score: 0.037
  59. Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer. PLoS One. 2016; 11(6):e0156910.
    View in: PubMed
    Score: 0.036
  60. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cancer. 2016 09 01; 122(17):2671-9.
    View in: PubMed
    Score: 0.036
  61. Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes. Ann Oncol. 2016 Apr; 27(4):635-41.
    View in: PubMed
    Score: 0.035
  62. Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation. Int J Radiat Oncol Biol Phys. 2016 Mar 15; 94(4):755-65.
    View in: PubMed
    Score: 0.035
  63. Superior Mesenteric Artery Margin of Posttherapy Pancreaticoduodenectomy and Prognosis in Patients With Pancreatic Ductal Adenocarcinoma. Am J Surg Pathol. 2015 Oct; 39(10):1395-403.
    View in: PubMed
    Score: 0.035
  64. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S1221-8.
    View in: PubMed
    Score: 0.034
  65. The number and ratio of positive lymph nodes affect pancreatic cancer patient survival after neoadjuvant therapy and pancreaticoduodenectomy. Histopathology. 2016 Jan; 68(2):210-20.
    View in: PubMed
    Score: 0.034
  66. Expression and clinical significance of epidermal growth factor receptor and insulin-like growth factor receptor 1 in patients with ampullary adenocarcinoma. Hum Pathol. 2015 Sep; 46(9):1315-22.
    View in: PubMed
    Score: 0.034
  67. Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer. Acta Oncol. 2015 Jul; 54(7):971-8.
    View in: PubMed
    Score: 0.033
  68. Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. Phys Biol. 2014 Nov 26; 11(6):065002.
    View in: PubMed
    Score: 0.033
  69. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer. Ann Surg Oncol. 2015 Apr; 22(4):1168-75.
    View in: PubMed
    Score: 0.032
  70. Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer? J Cachexia Sarcopenia Muscle. 2014 Dec; 5(4):307-13.
    View in: PubMed
    Score: 0.031
  71. Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest. 2014 Apr; 124(4):1525-36.
    View in: PubMed
    Score: 0.031
  72. Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. J Gastrointest Surg. 2014 Jan; 18(1):16-24; discussion 24-5.
    View in: PubMed
    Score: 0.030
  73. Morbidity and mortality after pancreaticoduodenectomy in patients with borderline resectable type C clinical classification. J Gastrointest Surg. 2014 Jan; 18(1):146-55; discussion 155-6.
    View in: PubMed
    Score: 0.030
  74. Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma. Histopathology. 2013 Dec; 63(6):841-51.
    View in: PubMed
    Score: 0.030
  75. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford). 2014 May; 16(5):430-8.
    View in: PubMed
    Score: 0.030
  76. A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy. Ann Oncol. 2013 Sep; 24(9):2349-53.
    View in: PubMed
    Score: 0.029
  77. The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. Invest New Drugs. 2013 Oct; 31(5):1375-83.
    View in: PubMed
    Score: 0.029
  78. Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis. Ann Surg Oncol. 2013 Jul; 20(7):2197-203.
    View in: PubMed
    Score: 0.029
  79. The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma. Ann Surg Oncol. 2013 Dec; 20 Suppl 3:S500-8.
    View in: PubMed
    Score: 0.029
  80. Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. J Gastrointest Surg. 2012 Sep; 16(9):1696-704.
    View in: PubMed
    Score: 0.027
  81. Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration. J Am Coll Surg. 2012 Jul; 215(1):41-51; discussion 51-2.
    View in: PubMed
    Score: 0.027
  82. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012 Dec 01; 118(23):5749-56.
    View in: PubMed
    Score: 0.027
  83. Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreaticoduodenectomy. Am J Surg Pathol. 2012 Apr; 36(4):552-9.
    View in: PubMed
    Score: 0.027
  84. Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. Am J Surg Pathol. 2012 Mar; 36(3):409-17.
    View in: PubMed
    Score: 0.027
  85. Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. HPB (Oxford). 2012 Jun; 14(6):365-72.
    View in: PubMed
    Score: 0.027
  86. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. Ann Surg Oncol. 2012 Jun; 19(6):2045-53.
    View in: PubMed
    Score: 0.027
  87. Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. J Gastrointest Surg. 2012 Jan; 16(1):68-78; discussion 78-9.
    View in: PubMed
    Score: 0.026
  88. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. Cancer. 2012 Jun 15; 118(12):3182-90.
    View in: PubMed
    Score: 0.026
  89. Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trial. Ann Surg Oncol. 2011 Dec; 18(13):3615-22.
    View in: PubMed
    Score: 0.026
  90. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer. 2010 Jul 14; 10:368.
    View in: PubMed
    Score: 0.024
  91. Challenges in the study of adjuvant chemoradiation after pancreaticoduodenectomy. Ann Surg Oncol. 2010 Apr; 17(4):950-2.
    View in: PubMed
    Score: 0.024
  92. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol. 2010 Jul; 17(7):1794-801.
    View in: PubMed
    Score: 0.023
  93. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs. 2011 Aug; 29(4):694-9.
    View in: PubMed
    Score: 0.023
  94. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009 Apr; 16(4):836-47.
    View in: PubMed
    Score: 0.022
  95. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest. 2008 Oct; 26(8):794-9.
    View in: PubMed
    Score: 0.021
  96. Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest New Drugs. 2008 Oct; 26(5):445-54.
    View in: PubMed
    Score: 0.021
  97. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008 May; 206(5):833-46; discussion 846-8.
    View in: PubMed
    Score: 0.020
  98. Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater. Int J Radiat Oncol Biol Phys. 2008 Mar 01; 70(3):735-43.
    View in: PubMed
    Score: 0.020
  99. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer. 2007 Jul 01; 110(1):47-55.
    View in: PubMed
    Score: 0.020
  100. Patterns of self-reported symptoms in pancreatic cancer patients receiving chemoradiation. J Pain Symptom Manage. 2007 Sep; 34(3):244-52.
    View in: PubMed
    Score: 0.019
  101. Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy? J Am Coll Surg. 2007 Mar; 204(3):347-55.
    View in: PubMed
    Score: 0.019
  102. Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer. 2006 Dec 01; 107(11):2589-96.
    View in: PubMed
    Score: 0.019
  103. Concurrent capecitabine and upper abdominal radiation therapy is well tolerated. Radiat Oncol. 2006 Oct 24; 1:41.
    View in: PubMed
    Score: 0.019
  104. The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006 Apr; 20(2):365-82.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.